



08-1525 *Dr*

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>	Application Number	10/762,566-Conf. #3220
	Filing Date	January 23, 2004
	First Named Inventor	Richard Franklin
	Art Unit	3761
	Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	Attorney Docket Number	20342/1202529-US1

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Third Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Form PTO/SB/08 (1 page) Copies of 4 references Certificate of Express Mailing (1 pg) Return Receipt Postcard
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	DARBY & DARBY P.C.		
Signature	<i>Jonathan M. Spinner</i>		
Printed name	Jonathan M. Spinner, Ph.D.		
Date	August 12, 2005	Reg. No.	57,268



Docket No.: 20342/1202529-US1
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Richard Franklin

Application No.: 10/762,566

Confirmation No.: 3220

Filed: January 23, 2004

Art Unit: 3761

For: FORMULATION AND METHODS FOR
THE TREATMENT OF
THROMBOCYTHEMIA

Examiner: Not Yet Assigned

THIRD INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In order to comply with the duty to disclose information under 37 CFR §1.56 and further to the Information Disclosure Statement mailed for this application on September 10, 2004 and the Supplemental Information Disclosure Statement mailed on May 25, 2005, Applicants submit herewith a Third Information Disclosure Statement pursuant to 37 CFR §§1.97 and 1.98. In particular, Applicants submit herewith a Form PTO/SB/08 (Substitute to Form PTO-1449) listing references for consideration by the Examiner. Copies of these references are attached and submitted herewith.

The attached references were originally listed within the Information Disclosure Statement mailed on September 10, 2004. However, it has come to our attention that some of the citations on the September 10, 2004 Form PTO/SB/08 contain typographical errors. The presently filed Form PTO/SB/08 corrects these errors and provides additional copies of the cited references.

It is believed that this IDS is being submitted before the mailing of a first Office Action on the merits and in accordance with the provisions of 37 CFR §1.97(b)(3). It is therefore believed that no fee is required for this submission. However, should it be determined that any fee is required for this application or that any refund is owed, then the Commissioner is hereby requested and authorized to charge the required fee(s) and/or credit the refund(s) owed to Deposit Account No. 04-0100 of Applicants' undersigned attorneys/agents.

It is respectfully requested that each document cited in these IDSs be given thorough consideration by the Examiner, and that each document be cited of record in the prosecution history. Although these IDSs are being submitted in compliance with 37 CFR §1.56, the citation of a document in these IDSs is not to be construed as an admission that such document is necessarily relevant or that the document is “prior art” to the present application. No representation is intended that the cited documents represent the results of a complete search or that any such search has been made.

Dated: August 12, 2005

Respectfully submitted,

By Jonathan M. Spenner
Jonathan M. Spenner, Ph.D.

Registration No.: 57,268
DARBY & DARBY P.C.
P.O. Box 5257
New York, New York 10150-5257
(212) 527-7700
(212) 527-7701 (Fax)
Attorneys/Agents For Applicant



Application No. (if known): 10/762,566; Conf. #3220

Attorney Docket No.: 20342/1202529-US1

Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. _____ in an envelope addressed to:

EV 691012210-US

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on August 12, 2005
Date

B.W. Kee

Signature

B.W. KEE

Typed or printed name of person signing Certificate

Registration Number, if applicable

Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Form PTO/SB/08 (1 page)
Copies of 4 cited references
Third Information Disclosure Statement (2 pages)
Transmittal Form (1 page)
Return Receipt Postcard

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO <h1>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h1> <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/762,566-Conf. #3220
				Filing Date	January 23, 2004
				First Named Inventor	Richard Franklin
				Art Unit	3761
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	20342/1202529-US1
Sheet	1	of	1		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
		PESCATORE, <i>et al.</i> (2000). Anagrelide: a novel agent for the treatment of myeloproliferative disorders. <i>Exp. Opin. Pharmacother.</i> 1:537-46
		GRIESSHAMMER, <i>et al.</i> (2001). Current treatment practice for essential thrombocythaemia in adults. <i>Exp. Opin. Pharmacother.</i> 2:385-93
		LANE, <i>et al.</i> (2001) Anagrelide metabolite induces thrombocytopenia in mice by inhibiting megakaryocyte maturation without inducing platelet aggregation. <i>Exp. Hematol.</i> 29:1417-24
		ERUSALIMSKY, <i>et al.</i> (2002). Is the platelet lowering activity of anagrelide mediated by its major metabolite 2-amino-5, 6-dichloro-3, 4-dihydroquinazoline (RL603)? <i>Exp. Hematol.</i> 30:625-6; author reply 626-7.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--